CME
Latest Episodes
Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Host: Jeffrey S. Weber, MD, PhD Host: Sapna Patel, MD Host: Jason J. Luke, MD, FACP Despite improved prognosis for melanoma patients due to advances in treatment options in recent years, survival rates for patients with metastatic diseas
How Do We Identify Patients with Localized Prostate Cancer Who Are at Increased Risk for Developing Metastatic Disease?
Host: Rana McKay, MD Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the
Should We Make Active Surveillance More Active for Localized Prostate Cancer?
Host: Neeraj Agarwal, MD Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of
What Is the Future of Neoadjuvant ARI Intensification in Localized Prostate Cancer?
Host: Rana McKay, MD Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the
Can ARIs Be Combined with Radiation Therapy in High-Risk Localized Prostate Cancer?
Host: Neeraj Agarwal, MD Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of
Case Study: How Do We Optimize Treatment Adherence with ARIs in Localized Prostate Cancer?
Host: Rana McKay, MD Host: Neeraj Agarwal, MD Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-ris
Expert Panel: What Is the Future of Early Intensification in Localized Prostate Cancer?
Host: Rana McKay, MD Host: Neeraj Agarwal, MD Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-ris
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
Host: Guy Young, MD Hemophilia A is an inherited or spontaneously occurring secondary hemostasis disorder caused by clotting factor VIII deficiency, which affects the formation and stabilization of clots. If left untreated, hemophilia A can caus
Meaningfulness of ISTH Chart Audit of In-hospital Mortality for ICH?
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limite
Meaningfulness of ISTH Chart Audit of In-hospital Mortality for GI Bleeds?
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limite
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast